OTCM
UTRS
Market cap0kUSD
Apr 04, Last price
0.00USD
Name
Minerva Surgical Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
50m
-3.47%
Net income
-34m
L+58.93%
CFO
-36m
L+58.93%
Profile
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||
Revenues | 50,294 -3.47% | |||
Cost of revenue | 81,193 | |||
Unusual Expense (Income) | ||||
NOPBT | (30,899) | |||
NOPBT Margin | ||||
Operating Taxes | 11 | |||
Tax Rate | ||||
NOPAT | (30,910) | |||
Net income | (34,112) 58.93% | |||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 36 | |||
BB yield | -0.56% | |||
| Debt | ||||
Debt current | 2,249 | |||
Long-term debt | 37,796 | |||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | 33,103 | |||
| Cash flow | ||||
Cash from operating activities | (35,567) | |||
CAPEX | (73) | |||
Cash from investing activities | (73) | |||
Cash from financing activities | (4,964) | |||
FCF | (43,490) | |||
| Balance | ||||
Cash | 6,942 | |||
Long term investments | ||||
Excess cash | 4,427 | |||
Stockholders' equity | (283,628) | |||
Invested Capital | 340,228 | |||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 1,440 | |||
Price | 4.47 -95.65% | |||
Market cap | 6,436 -82.14% | |||
EV | 39,539 | |||
EBITDA | (20,093) | |||
EV/EBITDA | ||||
Interest | 3,222 | |||
Interest/NOPBT | ||||